NASDAQ: DWTXDogwood Therapeutics Inc Stock
$5.37+1.10 (+25.76%)
Updated Apr 21, 2025
DWTX Price
$5.37
Fair Value Price
-$0.56
Market Cap
$10.26M
52 Week Low
$1.62
52 Week High
$29.28
P/E
-0.43x
P/B
-1.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.35M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.97
Operating Cash Flow
-$9M
Beta
0.8
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DWTX Overview
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DWTX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DWTX
Ranked#446 of 462
Ranked#446 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important DWTX news, forecast changes, insider trades & much more!
DWTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DWTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DWTX ($5.37) is overvalued by 1,053.93% relative to our estimate of its Fair Value price of -$0.56 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DWTX ($5.37) is not significantly undervalued (1,053.93%) relative to our estimate of its Fair Value price of -$0.56 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DWTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DWTX due diligence checks available for Premium users.
Valuation
DWTX fair value
Fair Value of DWTX stock based on Discounted Cash Flow (DCF)
Price
$5.37
Fair Value
-$0.56
Undervalued by
1,053.93%
DWTX ($5.37) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DWTX ($5.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DWTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DWTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.43x
Industry
-184.27x
Market
27.14x
DWTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.01x
Industry
4.04x
DWTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.7M
Profit Margin
0%
DWTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$94.3M
Liabilities
$30.0M
Debt to equity
-2.97
DWTX's short-term assets ($16.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DWTX's long-term liabilities ($26.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DWTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DWTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
$0.0
Financing
$15.3M
DWTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DWTX vs Biotech Stocks
Dogwood Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.